Press coverage about Akers Biosciences (NASDAQ:AKER) has trended positive recently, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akers Biosciences earned a news sentiment score of 0.26 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 46.733166127081 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern’s analysis:
Akers Biosciences (AKER) traded up $0.01 during mid-day trading on Wednesday, hitting $0.41. 6,267,300 shares of the stock traded hands, compared to its average volume of 18,956,416. Akers Biosciences has a one year low of $0.12 and a one year high of $2.90. The firm has a market cap of $10.17, a PE ratio of -0.70 and a beta of 1.09.
Separately, ValuEngine upgraded shares of Akers Biosciences from a “sell” rating to a “hold” rating in a report on Friday, December 1st.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/21/akers-biosciences-aker-getting-favorable-media-coverage-report-finds.html.
Akers Biosciences Company Profile
Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The companys marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.
Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.